Hedge Fund Manager Ubben Commits To Valeant Relationship

Jeffrey Ubben and his Hedge fund ValueAct are more strongly committed to their second largest holding, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), than ever before. Ubben made negative comments about Valeant, Allergan deal After ValueAct’s representative on the Valeant board, Mason Morfit, stepped down from his board seat in May to devote time to ValueAct’s largest holding, Microsoft Corporation (NASDAQ:MSFT), and Ubben subsequently made negative comments about Valeant’s acquisition about Allergan, Inc. (NYSE:AGN), whispers wondered if the hedge fund was still committed to its relationship with the medical roll-up firm. That changes with today’s announcement. “They’re basically saying: ‘We’re back…